In a significant breakthrough in India’s fight against Mucormycosis, commonly known as black fungus, Wardha-based Genetek Lifesciences Pvt. Ltd. successfully manufactured and rolled out its first batch of Amphotericin-B Emulsion injections. Amphotericin-B, regarded as a frontline antifungal therapy, was described by medical professionals as a vital drug in controlling the aggressive infection that had emerged in COVID-19 patients during the second wave.

The launch of the first batch came at a critical moment when hospitals across the country had reported acute shortages of Amphotericin-B. The sudden rise in Mucormycosis cases had placed unprecedented pressure on India’s pharmaceutical supply chain, and the availability of a locally manufactured, cost-effective version was seen as a major relief for patients and healthcare providers.

The Food and Drugs Administration (FDA) had granted approval for production on May 14, 2021, following which Genetek Lifesciences began preparing to scale up operations. The company stated that if raw material supplies were ensured, it could manufacture up to 20,000 vials per day, making a significant impact on national demand.

At the time, 11 states and Union Territories, including Maharashtra, Gujarat, Rajasthan, Delhi, Uttar Pradesh, and Madhya Pradesh, had already declared Mucormycosis an epidemic under the Epidemic Diseases Act, 1897. The rising number of cases highlighted the urgency for a steady and reliable supply of antifungal medicines.

The rollout of these injections demonstrated how regional pharmaceutical manufacturers could rise to the occasion during a public health emergency. Genetek Lifesciences not only filled an urgent supply gap but also set an example of how indigenous companies could contribute meaningfully to the nation’s healthcare resilience.